Introduction
Few cephalosporins have useful activity against Pseudomonas aeruginosa. Several catechol-substituted /Mactams have therefore been synthesized in order to investigate their anti-pseudomonal activity. (Ohi et al., 1986; Mochida et al., 1987; Nakagawa et al., 1987 Nakagawa et al., , 1989 Watanabe et al., 1987; Mochizuki et al., 1988; Ogino et al., 1990; Arisawa et al., 1991; Erwin et al., 1991; Wise et al., 1991; Arnould et al., 1992; Maejima, Inoue & Mitsuhashi, 1991; Jones & Erwin, 1992; Aszodi et al., 1994; Kolek et al., 1994) . The use of a catechol group on /Mactam structures enhances their penetration into bacterial cells by the /onB-dependent iron transport system (Curtis et al., 1988; Silley et al., 1990) . Although catechol-substituted cephalosporins show superior antipseudomonal activities compared with those of other cephalosporins, most of them have weak activity against Gram-positive bacteria. LB10517 is a parenteral cephalosporin that has a catechol moiety on the 7-oxime side-chain and shows potent activity against both Gram-positive and Gram-negative bacteria including P. aeruginosa (Figure 1 ). The in-vitro and in-vivo activities of LB10517 were compared with those of cefpirome, ceftazidime, ceftriaxone and cefoperazone, and stability to various /Mactamases and the time-kill curves were determined.
Materials and methods

Antimicrobial agents
LB10517 and cefpirome were synthesized at the Biotech Research Institute (LG Chem Research Park), Korea. Ceftazidime (Glaxo), cefotaxime (Hoechst), ceftriaxone (Sigma), cefoperazone (Sigma), cephaloridine (Sigma), cefoxitine (Sigma) and cefsulodine (Sigma) were used as standards.
Test organisms
Clinical isolates used in this study were collected at several hospitals in Korea between 1991 Korea between -1994 (Table I ). All isolates were maintained as suspensions in Trypticase Soy Broth at -70°C.
Susceptibility studies
The MICs of LB10517 and reference compounds against clinical isolates and /Mactamase-producing resistant strains were determined by the agar dilution method as described by the National Committee for Clinical Laboratory Standards (NCCLS, 1993) , using Mueller-Hinton medium (Difco Laboratories, Detroit, MI). Test strains were grown for 18 h in Mueller-Hinton Broth (MHB), diluted with fresh medium to a density of approximately 10 7 cfu/mL and applied to Mueller-Hinton Agar (MHA) plates containing serial dilutions of the antimicrobial agents, using an automatic MIC-2000 multipin inoculator (Dynatech Laboratories, Inc., Alexandria, VA.) to yield approximately KPcfu per spot. The MICs were determined after 18 h of incubation at 35°C. The concentrations of the bacterial suspensions were determined optically and were verified by standard colony counts on antibiotic-free agar plates. The MIC was considered to be the lowest concentration that completely inhibited growth on agar plates, disregarding a single colony or a faint haze caused by the inoculum.
Time kill study
Antibiotics at concentration of 1/4, 1/2, 1, 2 and 4 times the MIC were tested in the time-kill study. Test organisms were grown overnight, diluted to 10'cfu/mL and 1 mL was inoculated into fresh MHB with each antibiotic, resulting in a final inoculum of 10 3 cfu/mL. MHB without antibiotic was used as a control. At 2, 4, 6 and 24 h of incubation, 1 mL aliquots were removed, and viable cell counts were determined on MHA. The minimal bactericidal concentration (MBC), defined as the lowest concentration which gave more than 99.9% reduction in cfu after 18 h of incubation at 35°C (NCCLS, 1992) , was determined also by subculturing 100 /^L of culture broth onto antibiotic free MHA or antibiotic supplemented MHA.
In-vivo activity
The in-vivo activity of LB10517 was determined using a murine systemic infection model. Test organisms were cultured on Tryptic Soy Agar (Difco) at 35°C for 18 h and suspended in gastric mucin (Difco). Male ICR mice (19-21 g) in four groups of six mice were inoculated intraperitoneally with 0.5 mL of a bacterial suspension corresponding to an inoculum of 5-10 times the Minimal Lethal Dose (MLD). Four dose levels were used for each antibiotic, depending on the in-vitro antimicrobial activity of the compounds, and were administered subcutaneously at 1 and 4 h post-infection. The total number of mice surviving at each dose level was recorded on post-infection day 7 and the 50% protective dose (PDJO) was calculated by the method of Bliss (1952) . All untreated mice died within 2 days after infection.
For in-vivo activity in the respiratory tract infection (RTI) model, groups of 10 mice were exposed to a bacterial aerosol containing Klebsiella pneumoniae B-54 at 10* cfu/mL in a chamber for 20 min. Four dose levels of each antimicrobial were administered twice a day for 3 days, and the PDso was determined from the survival rates on post-infection day 7.
Stability to fi-lactamases
To determine /Mactamase stability, cell-free sonic extracts of /Mactamase-producing strains were prepared from mid-exponential phase cultures in Tryptone Soy Broth. The hydrolysis rate of the drugs by several /Mactamases was assayed in a temperature-controlled UV spectrophotometer (Shimadzu UV-2000) at 35°C. All antibiotic solutions were prepared immediately before use in 50 mM sodium phosphate buffer, and the reaction was followed at a wavelength which gave the maximum change in absorbance before and after hydrolysis. The stability of the drugs to hydrolysis was expressed relative to that of cephaloridine, which was taken to be 100%. The K m and V^ values were determined from hydrolytic rates at various substrate concentrations using the Lineweaver-Burk plot. The value calculated for VnuJKn can be taken as a measure of efficiency of hydrolysis, as defined by Pollock (1965) . (Kim et al., 1995) .
Induction of fl-lactamase
An overnight culture of Enterobacter cloacae 1194E was diluted 20-fold in 10 mL of MHB and incubated with shaking at 35°C. After 2.5 h of incubation (mid-log phase), test compounds were added as inducers. Incubation was continued for 2 h, and the cells were then washed twice with 50 mM phosphate buffer (pH 7.0). The cells were suspended in the same buffer and sonicated in ice water. Cell debris and unbroken cells were removed by centrifugation, and the resulting supernatant fluid was used as a crude enzyme. /Mactamase activity was determined with 100 fiM cephaloridine as the substrate (Kobayashi el al., 1986) , and the protein concentration was estimated by the method of Bradford (1976) with bovine serum albumen as the standard.
In-vitro frequency of resistant cells
Overnight cultures in MHB were inoculated onto agar plates containing the drug at concentrations of 1, 2, 4 and 8 times the MIC. The plates were incubated at 35°C for 48 h and the number of colonies on the drug-containing plates was determined. The ratio of the number of colonies on the drug containing plate to that on control plate was calculated as the frequency of resistance mutation.
Results
In-vitro antibacterial activity
LB10517 showed activity against a wide range of Gram-positive and Gram-negative bacteria including P. aeruginosa (Table I) . Against methicillin-susceptible strains of S. aureus (MSSA), the MIC*> of LB10517 was 0.25 mg/L, being 8-times lower than that of cefpirome. However, methicillin-resistant strains of S. aureus (MRSA) and Staphylococcus epidermidis (MRSE) were highly resistant to all cephalosporins. Against methicillin-susceptible 5. epidermidis (MSSE), Streptococcus pyogenes and Enterococcus faecalis, LB10517 was more active than the reference compounds. LB10517 was also highly active against most members of the family Enterobacteriaceae tested, 90% of which were inhibited at concentration of less than 1 mg/L, the exception being Citobacter freundii, E. cloacae, Enterobacter aerogenes, and Serratia marcescens. Against Escherichia coli, E. aerogenes and Proteus vulgar is, LB10517 was as active as cefpirome, while against C. freundii, E. cloacae, Klebsiella pneumoniae and Proteus mirabilis, it was more active than cefpirome. Against Klebsiella oxytoca, Morganella morganii and Salmonella spp., LB10517 was less active than cefpirome but was as active as ceftazidime and ceftriaxone. LB10517 also showed potent activity against P. aeruginosa, the MIG» being 2 mg/L and its activity being higher than that of all the reference compounds. LB10517 showed similar activity against Acinetobacter calcoaceticus to that of cefpirome but was 8-fold more active than ceftriaxone.
In-vitro antibacterial activity of LB10517 was also tested against 39 resistant strains producing various /3-lactamases and was found to be more active than the reference compounds (Table II) . 
Time-kill study
The bactericidal activity of LB10517 was compared with that of cefpirome. Time-kill tests shows that LB10517 had rapid bactericidal activity against S. aureus ATCC 6538p, E. coli 851E and P. aeruginosa 1912E at two and four times the MIC, and regrowth after 24 h incubation was not detected (Figure 2) . MBCs of LB10517 in MHB were identical to or at most twice as high as the MICs. 
In-vivo activity in mice
The protective effects of LB10517 on systemic infections in mice induced by S. aureus giorgio, S. pyogenes 77A, S. pneumoniae III and P. aeruginosa 1912E, respectively, were compared with those of cefpirome and ceftazidime. Table III shows that LB10517 exhibited potent protective effects. Against S. aureus giorgio infection, LB10517 was more potent than cefpirome and ceftazidime. Against P. aeruginosa 1912E infection, LB10517 was also more active than cefpirome and ceftazidime. Against S. pneumoniae III infection, the PDw of LB 10517 was 3.15mg/kg, comparable to that of cefpirome (4.55 mg/kg), but better than ceftazidime (43.40 mg/kg). Against S. pyogenes 77A infection, LB10517 was less active than cefpirome but it was more potent than ceftazidime. The RTI model in mice was used for the evaluation of the protective effect of LB10517 and other reference antibiotics (Table TV) . Although in-vitro activity of LB10517 against K. pneumoniae B-54 was 16-fold less than that of cefpirome, LB10517 showed a comparable in-vivo protective activity to that of cefpirome in the RTI model.
Stability to P-lactamases
The /Mactamase stabilities of LB10517 and reference compounds were evaluated by measuring the relative hydrolysis rates for several types of /Mactamases. Table V shows that LB10517 was the most stable to the hydrolysis by /Mactamases. The enzyme kinetic parameters of LB10517 and reference compounds for TEM-9 /Mactamase were determined by measuring the K u V^ and K^ values (Table VI) . LB10517 had better physiological efficiency (K^/A^,) than the other cephalosporins. Against resistant strains which can produce /Mactamases, LB10517 had potent antibacterial activity as shown in Table II . Figure 3 shows the activities of the enzyme induced in E. cloacae 1194E by LB10517 and other cephalosporins. Although most of test compounds induced /Mactamase even at low concentrations, below their MICs, LB10517 and ceftazidime did not induce /Mactamase at high concentration. A dose-dependent increase in induction rate was also observed with other compounds. LB10517 was the weakest inducer of the compounds tested. •Classification by Bush, Jacoby & Medeiros (1995) . 'Rate of hydrolysis relative to that of cephaloridine •The rate of hydrolysis was too slow to determine. 
Induction of fi-lactamase
In-vitro frequency of resistant cells
The frequency of highly resistant cells which can survive in the presence of LB 10517 at the concentrations of 1 x MIC or higher was compared with that of cefpirome. Figure 4 shows the frequency of resistant cells of E. coli, P. aeruginosa and 5. aureus, respectively, to LB10517 and cefpirome. LB10517 induced more resistant cells than cefpirome in E. coli and P. aeruginosa, but in 5. aureus the frequency was less than that of cefpirome.
Discussion
LB10517, a parenteral catechol-substituted cephalosporin, has a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria. Although most catechol-substituted cephalosporins have weak activity against Gram-positive bacteria, LB10517 showed more potent activity against these than cefpirome. The excellent protective effect of LB 10517 in the mouse infection models was well-correlated with its in-vitro activity. LB10517 was stable to hydrolysis by clinically important /f-lactamases such as TEMs, produced by members of the family Enterobacteriaceae. LB10517 therefore showed potent activity against /Mactamase-producing bacteria.
Research on /Mactam antimicrobials is concentrated on the development of new cephalosporins that might overcome the problem of emerging resistance and might enable the dose frequency to be reduced. From this point of view, catechol-substituted cephalosporins might have advantages over the classical cephalosporins without a catechol moiety. Cephalosporins with a catechol moiety at 7 position can utilize the /oflfi-dependent iron transport system in addition to porin proteins to enter the bacterial periplasmic space (Watanabe et al., 1987; Curtis et al., 1988; Silley et al., 1990) . This dual mode of entry may result in increased potency, especially as the infecting organism will be in an iron-deficient state in which the tonB gene product would initiate the active transport of iron-chelated catechols across the bacterial outer membrane. Thus, the excellent in-vivo activity of LB 10517 in mice may be partly attributable to its facilitated entry into bacterial cells in low-iron environments. This characteristic may offer an advantage in overcoming the resistance of P. aeruginosa and the other Gram-negative bacterial mutants that have a strong permeability barrier. Though the other important characteristics of LB10517 were that it was very stable to hydrolysis by various /Mactamases and that it showed a good pharmacokinetic profiles in animals (Kwak et al., 1994) , it may also have disadvantages. Firstly, those compounds with a catechol moiety might be metabolized rapidly in the liver. If the catechol-substituted compounds are methylated in vivo they will lose their antibacterial activity against Gram-negative bacteria (Ohi et al., 1987) . However, the superior efficacy in vivo coupled with results of an in-vitro metabolism study using liver microsomal fraction (data not shown), suggested that LB10517 might not be appreciably metabolized by enzymes such as catechol O-methyl transferase. Secondly, another possible disadvantage of catecholsubstituted cephalosporins is that these compounds induced resistant mutants at high frequency which lacked the active iron transport system derived from mutations at the tonB locus (Hartmann & Braun, 1980) . However it is doubtful whether these mutants, which require a high level of iron for normal growth, are able to survive in the iron-limited environment of their host. These findings suggest that LB10517 might overcome these two possible disadvantages and, together with a preliminary safety study, also suggest that LB10517 may be a promising new parenteral cephalosporin deserving further development.
